Jeffrey Glaze, MD
Nephrology · Homewood, ALNPI 1255389896
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,850 of the $98,415 with a category attached, or 87.2%. AstraZeneca accounts for 61.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $61,351 and has fallen 100.0% since, to $21 in 2025. Among nephrology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $451.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$60K
- Amgen$37K
- Travere Therapeutics, Inc.$259
- Akebia Therapeutics Inc$234
- Vifor Pharma, Inc.$221
- Fresenius USA Marketing, Inc.$139
- plus $517 from 10 others
What the payments were for
- Speaking & faculty fees$85,85087%
- Travel & lodging$7,0517%
- Food & beverage$5,4946%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 96 | $60,346 |
| Amgen(2 entities) | 56 | $36,698 |
| Travere Therapeutics, Inc. | 10 | $259 |
| Akebia Therapeutics Inc | 11 | $234 |
| Vifor Pharma, Inc. | 8 | $221 |
| Fresenius USA Marketing, Inc. | 8 | $139 |
| Bayer | 5 | $88 |
| OPKO Pharmaceuticals, LLC | 5 | $84 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Calliditas Therapeutics US Inc. | 3 | $60 |
| Aurinia Pharma U.S., Inc. | 3 | $55 |
| GSK | 3 | $53 |
| Kyowa Kirin, Inc. | 2 | $41 |
| Mallinckrodt Enterprises LLC | 2 | $25 |
| Baxter Healthcare | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$98,415 in reported general payments places this provider in the 95th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 150 | $135,692 |
| KerendiaFinerenone | 28 | $22,225 |
| JardianceEmpagliflozin | 15 | $21,274 |
| VeltassaPatiromer Calcium Sorbitex | 14 | $14,596 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $13,827 |
| Sevelamer Carbonate | 40 | $6,582 |
| Losartan Potassium | 127 | $1,980 |
| Calcium Acetate | 20 | $1,576 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,102 |
| Bumetanide | 20 | $997 |
| Furosemide | 93 | $986 |
| Potassium Chloride | 50 | $844 |
| Chlorthalidone | 27 | $826 |
| Nifedipine ErNifedipine | 18 | $675 |
| Telmisartan | 20 | $598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $60,346 | $149,520161 claims |
| BayerKerendia | $88 | $22,22528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 164 nephrology providers in Alabama.
Other nephrology in Homewood
- Thomas OzbirnHomewood$133K
- Harold GilesHomewood$18K
- Michael QuadriniHuntsville$323K
- Dana RizkBirmingham$196K
- Sumeet MunjalMontgomery$191K
- Eric WallaceBirmingham$172K
- Phillip MadoniaAlabaster$165K
- David WarnockBirmingham$128K
- Michal MrugBirmingham$73K
- Vineeta KumarBirmingham$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.